Artículos

Publicado el 29 de octubre de 2002

Tratamiento con medicación para reducir la Insulina

Sindrome de ovario poliquístico

El síndrome de ovario poliquístico se caracteriza por anovulación e hiperandrogenismo.

Autor/a: Dr. Perloe, M.

Fuente: ObGyn Publications

1. Velazquez EM, Mendosa S, Hamer T, Sosa F, Glucck CJ. Metformin therapy in women with polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating menstrual regularity and pregnancy. Metabolism 1994,43:647_655.

2. Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450cl7alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. New England J Medicine 1996,335:617_623.

3. Utiger RD. Insulin and the polycystic ovary syndrome. New England J Medicine 1996,335:657_658

4. Dunaif A, Scott D, Finegood D, Quintana ma B, Whitcomb R. The insulin sensitizing agent Troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome Endocrinol Metab 1996;81:3299_3306